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T cells and the allergic 
response
Immune tolerance can develop against 
any immune-activating substance, and 
multiple mechanisms mediate this pro-
cess. Deregulation of immune tolerance 
may lead to the development of allergies, 
asthma, tumors, chronic infections, rejec-
tion of transplanted organs, graft-versus- 
host disease, and many autoimmune dis-
eases. Allergic diseases are character-
ized by the induction of a type 2 immune 
response that includes Th2 cells and type 
2 innate lymphoid cells (ILC2s), together 
with the production of allergen-specific 
IgE antibodies and increased eosinophil 
numbers in the affected tissues and some-
times in peripheral blood (1). Although 
there are many different ways to treat 
allergic disease–associated symptoms, 
currently, the only long-term curative 
treatment is allergen-specific immuno-
therapy (AIT), which involves the adminis-
tration of increasing doses of the causative 
allergen. Over time, AIT induces a state of 
allergen-specific immune tolerance. AIT 
has been performed for more than 100 
years, though it has only been within the 
past two decades that the mechanisms 
that mediate the action of AIT have been 
slowly uncovered (2). After the discovery 
of Th1 and Th2 cells in 1986 (3), it was sug-
gested that a Th2 response underlies the 
development of allergic diseases and that 
Th1 responses are predominant in infec-
tions and autoimmunity. Following these 
initial findings, the general dogma was 
that a switch toward a Th1 response would 
be required for the successful treatment of 
allergies by AIT, and a switch toward a Th2 
response would be beneficial for the treat-
ment of autoimmunity.
In the mid-1990s, our group was work-
ing on the mechanisms of action of AIT in 
conventional and T cell epitope peptide 
immunotherapies (4, 5). We were using 
honey bee venom allergy and its major 
allergen phospholipase A2 as a model 
to investigate antigen/allergen-specific 
immune response development in humans 
(4). In a 1996 article published in the JCI, 
we demonstrated that allergen-specific 
T cell tolerance was induced during the 
course of AIT (4). Two months after the 
beginning of venom immunotherapy, the 
proliferation of T cells specifically target-
ing phospholipase A2 and its T cell epitope 
peptides as well as the secretion of both 
Th2 (IL-4, IL-5, and IL-13) and Th1 (IL-2 
and IFN-γ) cytokines were abolished. 
These data directly challenged the dogma 
that switching the balance between Th1 
and Th2 responses is playing a role in treat-
ment and suggested that the development 
of full T cell tolerance and suppression of 
both Th1 and Th2 subsets are taking place. 
As a control antigen, we demonstrated 
that tetanus toxoid–induced T cell prolif-
eration and cytokine production remained 
unchanged following venom-specific AIT, 
demonstrating that the immune tolerance 
was specific to venom antigens and did 
not extend to other antigens. In addition, 
the state of T cell tolerance induced by 
AIT was altered in vitro by treatment with 
IL-2, IL-4, and IL-15. This was one of the 
first demonstrations that antigen-specific 
effector T cells have plasticity, suggest-
ing that microenvironmental cytokines 
are important for determining success 
or failure in AIT (4). During these exper-
iments, we were fortunate to be working 
with highly pure synthetic peptides and 
purified bee venom antigens collected in 
a sterile way. This enabled us to demon-
strate immune tolerance, because any 
lipopolysaccharide contamination during 
collection and extraction of environmen-
tal allergens, such as house dust mites and 
pollens, would have led to results showing 
a skew from Th2 toward Th1.
IL-10–producing Tregs in 
immune tolerance
In hindsight, our research continued to 
elucidate the molecular and cellular mech-
anisms of T cell tolerance to allergens, and 
in our 1998 study published in the JCI, we 
demonstrated that human IL-10–produc-
ing Tregs (Tr1 cells) are linked to an anti-
gen-specific suppressor function (Figure 1 
and ref. 6). Intracytoplasmic cytokine stain-
ing of circulating lymphocytes revealed that 
IL-10 was initially produced by CD4+CD25+ 
allergen–specific Tr1 cells and then by B 
cells and monocytes. These IL-10–secret-
ing Tr1 cells were substantially increased 
as early as seven days after the start of 
bee venom AIT in allergic individuals. Fol-
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to allergens, but also in protecting the 
host from exaggerated inflammatory 
responses to pathogens as well as to auto-
immune diseases (30). IL-10 directly 
inhibits T cells through suppression of 
CD28- and ICOS-dependent T cell costim-
ulation (31). In addition, IL-10 inhib-
its the production of proinflammatory 
cytokines, chemokines, and chemokine 
receptors as well as the expression of 
MHC class II and costimulatory mole-
cules CD80/CD86 on monocytes/macro-
phages and dendritic cells (30).
In addition to T cell regulation, IL-10 
secreted from Tr1 cells plays a major role 
in the induction of IgG4 and suppression 
of IgE (6, 32). Moreover, it was recently 
demonstrated that IL-10–secreting B reg-
ulatory (Br1) cells essentially contribute 
to allergen tolerance (ref. 33 and Figure 1). 
Phospholipase A2–specific Br1 cells from 
nonallergic beekeepers and those that 
are induced after AIT showed increased 
expression of IL-10 with an antigen-spe-
cific suppressor capacity. A major finding 
of this study was that IgG4 production is 
specifically confined to Br1 cells. IgG4 rep-
resents a noninflammatory Ig isotype that 
does not activate complement and plays an 
IgE-blocking antibody role for the degran-
ulation of mast cells and basophils (33).
Conclusions
Specific Tr1 cells and immune tolerance 
development are essential for the induc-
tion and maintenance of healthy immune 
responses to allergens. The relationship 
between clinical allergen tolerance and 
immune tolerance has been observed 
by direct analysis of the affected tissues 
and skin during late-phase responses in 
humans who have undergone AIT with 
whole allergen and T cell epitope peptides 
as well as in individuals who have been 
exposed to naturally high doses of aller-
gens. As of today, the concept that Tr1 cells 
mediate antigen-specific T cell tolerance 
has been demonstrated and generally 
accepted after the publication of several 
thousand studies on immune regulation.
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expressing Th3 cells. It has been repeat-
edly shown that all three subsets of iTregs 
coexist and overlap in many immune tol-
erance–related situations in humans. For 
example, antigen-specific CD4+ T cells 
that express IL-10, TGF-β, and FOXP3, 
or some combination of these mark-
ers, increase in nasal biopsies (12, 15–17) 
and peripheral blood (7–9) in response to 
AIT at the healing phase.
Tr1 cells have been shown to be impor-
tant for the maintenance of a healthy 
immune response in different diseases, such 
as allergy, many autoimmune conditions, 
transplantation tolerance, and graft-versus-
host disease in both humans and mice (13, 
18–26). Although IL-10 is the main cytok-
ine produced by Tr1 cells, these cells also 
produce TGF-β and low-to-medium levels 
of IFN-γ and IL-5, but not IL-4 or IL-2 (27, 
28). It took almost a decade to demonstrate 
that human Tr1 cells suppress effector T 
cell responses by multiple mechanisms that 
depend on IL-10, TGF-β (7), PD-1, CTLA-4 
(29), and histamine receptor 2 (H2R) (13).
IL-10 has a potent immunosuppres-
sive capacity that is crucial not only for 
the establishment of peripheral tolerance 
lowing these initial findings, one major 
question was whether these Tr1 cells also 
develop during other types of AIT against 
different allergens. It took many years to 
demonstrate that Tr1 cells are generated in 
response to other immunotherapies such 
as sublingual immunotherapy, other aller-
gens such as grass pollen and house dust 
mites, and peptide immunotherapies in 
allergy and autoimmune diseases (7–12). In 
addition, Tr1 cells were demonstrated to be 
present in high-dose exposure to allergen 
models, such as nonallergic beekeepers and 
cat owners (6, 13, 14).
Tr1 cells and recently discovered 
Br1 cells support a healthy 
immune response to allergens
Studies during the past two decades have 
demonstrated that there are two broad 
subsets of CD3+CD4+ Tregs. One subset 
is the naturally occurring thymus-derived 
CD4+CD25+ FOXP3+ Tregs, also called nat-
ural Tregs (nTregs), and the other subset is 
the inducible Tregs (iTregs). Three main 
subsets of iTregs have been characterized: 
FOXP3-expressing iTregs, CD4+FOXP3- 
IL-10–producing Tr1 cells, and TGF-β–
Figure 1. Mechanisms of allergen tolerance. The induction of allergen-specific Tregs, which switch 
from allergen-specific Th2 cells is one of the initial events in the development of allergen tolerance. 
The effector cells of allergic inflammation — mast cells, basophils, and eosinophils — are regulated 
by suppressive and regulatory functions of Tregs in several ways. Treg-secreted IL-10 and TGF-β 
suppress these cells. Tregs also suppress Th2 cells and their cytokines, preventing the provision of 
survival factors for these allergy effector cells. IL-10 and TGF-β suppress IgE production by B cells, and 
meanwhile, IL-10 induces IgG4. IL-10–producing regulatory B cells (Bregs) play a role in suppression 
of allergen-specific T cells and mainly switch to IgG4-producing plasma cells. H2R plays a role in the 
suppression of Th2 cells, inflammatory dendritic cells, and basophils.
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